

References

Y-22

1. Miotto K, Hillhouse M, Donovan R, et al. Comparison of buprenorphine treatment for opioid dependence in three settings. *Journal of Addiction Medicine*. 2012; 6(1):68-76.
2. Sittambalam C, Vij R, Ferguson. Buprenorphine outpatient outcomes project: Can Suboxone be a viable outpatient option for heroin addiction? *Journal of Community Hospital Internal Medicine Perspective*. 2014; 14:4.
3. U.S. Department of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction.
4. Liebschutz J, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. *The Journal of the American Medical Association Internal Medicine*. 2014; 174(8):1369-76.
5. Sigmon S, Dunn K, Saulsgiver K, et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. *The Journal of the American Medical Association Psychiatry*. 2013; 70(12):1347-54.
6. Dugosh K, Abraham A, Seymour B, et al. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. *Journal of Addiction Medicine*. 2016; 10: 93–103.
7. Fiellin D, Schottenfeld R, Cutter C, et al. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence a randomized clinical trial. *The Journal of the American Medical Association Internal Medicine*. 2014; 174(12):1947-1954.
8. Davoli M, Amato L, Clark N, et al. The role of Cochrane reviews in informing international guidelines: A case study of using the grading of recommendations, assessment, development, and evaluation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. *Society for the study of Addiction*. 2015; 110(6):891-8.
9. American Society of Addiction Medicine (ASAM). National practice guideline for the use of medications in the treatment of addiction involving opioid use. American Society of Addiction Medicine. 2015.
10. Veterans Health Administration/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of substance use disorders (SUD). Veterans Health Administration, Department of Defense. 2015.
11. Farmer C, Lindsay D, Williams J, et al. Practice guidance for buprenorphine for the treatment of opioid use disorders: Results of an expert panel process. *Substance Abuse*. 2015; 36(2): 209–216.
12. The American Society of Addiction Medicine (ASAM). National practice guideline for the use of medications in the treatment of addiction involving opioid use. 2015.
13. Bonhomme J, Shim R, Gooden R, et al. Opioid addiction and abuse in primary care practice: A comparison of methadone and buprenorphine as treatment options. *Journal of the National Medical Association*. 2012; 104(0): 342–350.
14. Murthy V. Ending the opioid epidemic — A call to action. *The New England Journal of Medicine*. 2016; 375(25):2413-2415.

15. Dowell D, Haegerich TM, Chou R. Centers for Disease Control and Prevention (CDC) guideline for prescribing opioids for chronic pain-United States, 2016. *Journal of the American Medical Association*. 2016; 315(15):1624-1645.
16. 42 CFR 8.12 - Federal opioid treatment standards. April 2017.
17. Substance Abuse and Mental Health Services Administration (SAMHSA). Medication and Counseling Treatment. 2015.
18. United States Department of Labor. Mental health and substance use disorder parity. The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
19. Pennsylvania Act 106, (of 1989), 40 P.S. §§ 908-1 – 908-8. Pennsylvania benefit plans, drug and alcohol use and dependency coverage; Notice 2003-06. Pa.B. Doc. No. 03-1566. 2003.